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The NALP3-inflammasome is a protein complex that stimulates caspase-1 activation to 
promote the processing and secretion of proinflammatory cytokines. Recent work indi-
cates that the NALP3-inflammasome can be activated by endogenous “danger signals” as 
well as compounds associated with pathogens (Kanneganti et al., 2006; Mariathasan et al., 
2006; Martinon et al., 2006; Sutterwala et al., 2006). Here, we discuss new insights into the 
regulation of caspase-1 activity in the inflammatory response.Caspase-1 regulates the processing and secretion 
of three interleukin (IL)-1 family members: IL-1β, IL-
18, and IL-33. Both IL-1β and IL-18 are highly potent 
proinflammatory cytokines (Dinarello, 2002). IL-18 
induces interferon γ expression and secretion from 
IL-12-primed naïve T cells to promote the differentia-
tion of type 1 helper T cells. IL-33 has recently been 
identified as the ligand of the IL-1 receptor family pro-
tein ST2 and promotes responses mediated by type 2 
helper T cells (Schmitz et al., 2005). Upon cleavage of 
their proforms by caspase-1, these cytokines become 
active and are secreted. Thus, caspase-1 activity is 
critical for the inflammatory response.
NALP3, also known as cryopyrin or CIAS, encodes a 
protein that regulates the activity of caspase-1 (Figure 
1). The importance of caspase-1 in inflammation is dem-
onstrated by the fact that gain-of-function mutations in 
the NALP3 gene cause three autoinflammatory diseases: 
Muckle-Wells syndrome, familial cold autoinflammatory 
syndrome, and neonatal-onset multisystem inflamma-
tory disease. Collectively, these diseases are called 
cryopyrin-associated periodic syndromes (CAPS). Both 
CAPS and rheumatoid arthritis have been effectively 
treated by the administration of an IL-1 receptor antago-
nist, supporting the central role of IL-1 in the pathogen-
esis of these diseases. Thus, learning how caspase-1 
activation is regulated is crucial for understanding the 
pathogenesis of these autoinflammatory disorders.
Similar to the activation of caspase-8 or -9 by the Apaf-
1-apoptosome or Fas/CD95-DISC, respectively, it has 
been speculated that caspase-1 may be activated by a 
molecular platform termed an “inflammasome.” Tschopp 
and colleagues have proposed three types of inflamma-
some based on biochemical analysis of three Apaf-1-like 
proteins, NALP1, NALP2, and NALP3. In the case of the 
NALP3-inflammasome, NALP3 binds to two adaptor pro-teins, ASC and CARDINAL, both of which in turn bind 
to caspase-1, so that the complex can attract two cas-
pase-1 molecules (Agostini et al., 2004). It is assumed 
that a specific ligand induces assembly and activation of 
the NALP3-inflammasome, but its identity is unknown. 
Because other Apaf-1-like proteins such as Ipaf, NALP6, 
NALP10, and NALP12 modulate caspase-1 activity, addi-
tional types of caspase-1-activating platforms are likely to 
exist, each being activated by its own specific ligand.
Activation of Caspase-1 via ASC and Ipaf
Macrophages are known to secrete IL-1β in response to 
serial stimulation with lipopolysaccharide (LPS) and sub-
sequent treatment with a high concentration of ATP (Fer-
rari et al., 2006). LPS is required both to induce expression 
of pro-IL-1β and to prime cells for caspase-1 activation in 
response to ATP. The effect of ATP is mediated by an iono-
tropic ATP receptor, P2X7, which upon activation causes a 
rapid K+ efflux from the cytosol. Because release of IL-1β 
is also triggered by potassium ionophores, membrane-
permeabilizing agents, pore-forming agents, and deple-
tion of K+ from cell culture media, the efflux of cytosolic K+ 
is thought to be a trigger of caspase-1 activation.
The bacterium Salmonella typhimurium is also known to 
activate caspase-1 in macrophages. S. typhimurium pos-
sesses machinery to hijack mammalian epithelial cells, 
called the type-III secretion system (TTSS). The TTSS 
injects a series of bacterial products into mammalian cells 
creating a hospitable environment for bacterial entry and 
growth. When S. typhimurium is phagocytosed by mac-
rophages, the TTSS induces rapid caspase-1-dependent 
cell death, which is thought to be a strategy for Salmonella 
to escape the host phagocytes. Although the molecular 
mechanism by which the TTSS activates caspase-1 is not 
fully understood, bacterial compounds that are injected into 
the cytosol of macrophages are speculated to play a role.Cell 126, August 25, 2006 ©2006 Elsevier Inc. 659
Figure 1. Multiple Pathways Activate Caspase-1
Various bacterial compounds and endogenous molecules that are released from injured cells activate caspase-1 through the NALP3-inflamma-
some. Serial stimulation with TLR ligands plus ATP or pore-forming agents activate the NALP3-inflammasome (Mariathasan et al., 2006; Martinon 
et al., 2006; Sutterwala et al., 2006). TLR ligands prime cells to respond to ATP or pore-forming agents possibly by inducing expression of an 
unidentified gene downstream of NF-κB activation. ATP or pore-forming agents induce a rapid K+ efflux from cells, which triggers the activation 
of the NALP3-inflammasome. Previous pharmacological studies suggest that this pathway is mediated by Ca2+ release from intracellular stores, 
calcium-independent phospholipase A2, and AG126-sensitive protein tyrosine kinases. Bacterial RNA and imidazoquinoline compounds activate 
caspase-1 in a manner dependent on NALP3, but this activation is independent of TLRs (Kanneganti et al., 2006). LPS has been shown to activate 
caspase-1 in an ASC-dependent manner (Yamamoto et al., 2004), but it is not dependent on NALP3. A moiety of bacterial peptidoglycan, MDP, 
was shown to activate caspase-1 in human monocytic cells (Martinon et al., 2004) perhaps through Nod2. Monosodium urate (MSU) and calcium 
pyrophosphate dihydrate (CPPD), associated with gout and pseudogout, respectively, activate the NALP3-inflammasome in a manner dependent 
on a colchicines-sensitive process (Martinon et al., 2006). Overlap between the MSU/CPPD pathway and the pathway for K+ efflux is still unclear. In 
addition to the NALP3-inflammasome other NLR/CATERPILLER proteins appear to activate caspase-1 in response to various pathogens. Viral infec-
tion may activate ASC through an unknown pathway (Johnston et al., 2005). The bacterium Francisella tularensis activates caspase-1 through ASC 
but not through NALP3 or Ipaf. Instead this may involve another NLR/CATERPILLER protein (Mariathasan et al., 2006). The Salmonella typhimurium 
type-III secretion system activates caspase-1 through Ipaf (Mariathasan et al., 2004), whereas the Legionella pneumophila type-IV secretion system 
activates caspase-1 through Birc1e/NAIP5C57BL/6 and Ipaf (Zamboni et al., 2006). Recently, intracellular flagellin was shown to play a role in the Ipaf 
and/or NAIP5-mediated pathways (Franchi et al., 2006; Miao et al., 2006; Molofsky et al., 2006; Ren et al., 2006). Bacillus anthracis lethal toxin can 
activate caspase-1 via NALP1b129S1 (Boyden and Dietrich, 2006).Using mice lacking either ASC or Ipaf, Dixit and col-
leagues have demonstrated that the induction of cas-
pase-1 activation by LPS plus ATP or by S. typhimu-
rium are mediated by two distinct signaling pathways 
(Mariathasan et al., 2004). They showed that macro-
phages lacking ASC are unable to activate caspase-1 
in response to both LPS plus ATP and S. typhimurium, 
whereas Ipaf-deficient macrophages are impaired 
only in the caspase-1 activation induced by S. typh-
imurium. This finding implies that ASC shares a role in 
both pathways of caspase-1 activation, and that Ipaf 
mediates only the signal from Salmonella as a factor 
upstream of ASC.
Activators of the NALP3-Inflammasome
ATP and Bacterial Pore-Forming Toxins
NALP3 is required by murine macrophages for caspase-1 
activation in response to LPS plus ATP, but not in response 
to infection by S. typhimurium (Mariathasan et al., 2006; 
Martinon et al., 2006; Sutterwala et al., 2006). Moreover, 
other Toll-like receptor (TLR) ligands (lipid-A, lipoteichoic 
acid, lipoprotein, CpG oligodeoxyribonucleotides, and 
imidazoquinoline compounds) also prime the cells to 660 Cell 126, August 25, 2006 ©2006 Elsevier Inc.activate caspase-1 in response to ATP; other inducers of 
K+ efflux, such as nigericin and maitotoxin, also promote 
caspase-1 activation in a NALP3-dependent manner. 
Thus, the NALP3-inflammasome seems to be activated 
by serial stimulation by TLR ligands followed by K+ efflux. 
Infection by Listeria monocytogenes and Staphylococcus 
aureus also induces caspase-1 activation in LPS-primed 
macrophages in a manner dependent on NALP3 and ASC 
(Mariathasan et al., 2006). Because these bacteria pos-
sess toxins that cause pore formation in the cytoplasmic 
membrane of host cells, the effect of these bacteria on 
the NALP3-inflammasome may be explained by K+ efflux 
caused by these toxins. Indeed, Dixit’s group has shown 
that Listeria lacking the pore-forming toxin listeriolysin O 
are incapable of activating caspase-1.
It is unclear which ligand directly activates the NALP3-
inflammasome. However, it is likely that TLR stimulation 
leads to the induction of genes, such as NALP3 and cas-
pase-11, that are required for caspase-1 activation, and 
that K+ efflux is an upstream trigger of NALP3 activation 
(Ferrari et al., 2006; Mariathasan et al., 2006; Sutterwala 
et al., 2006). Pharmacological studies have revealed 
that IL-1β secretion induced by ATP is mediated by K+ 
efflux, release of intracellular Ca2+ stores, and the activi-
ties of protein tyrosine kinases and calcium-independ-
ent phospholipase A2. The relationship between these 
events and the processing and release of IL-1β are still 
not clear, although NALP3 may recognize an endog-
enous molecule generated by these processes.
Uric Acid and Calcium Pyrophosphate Dihydrate
In addition to ATP, Tschopp and colleagues found 
that crystals of monosodium urate (MSU) and cal-
cium pyrophosphate dihydrate (CPPD), the causative 
agents of gout and pseudogout, respectively, induce 
caspase-1 activity in a manner dependent on the 
NALP3-inflammasome (Martinon et al., 2006). MSU 
was identified as an active component of the adjuvant 
activity of UV-injured mammalian cells and has been 
demonstrated to activate dendritic cells in vitro (Shi 
et al., 2003). Thus, MSU might be a “danger signal” 
released from damaged cells that results in the activa-
tion of the immune system (Matzinger, 2002).
Because caspase-1 activation by MSU and CPPD 
crystals does not require TLR signaling and was not 
blocked by antagonists of the P2X7 receptor, the MSU/
CPPD pathway for activating the NALP3-inflammasome 
may act in parallel with the ATP pathway. Interestingly, 
caspase-1 activation by MSU and CPPD, but not by ATP, 
was blocked by colchicine, an inhibitor of tubulin polym-
erization that is used for the treatment of gout and pseu-
dogout. These findings suggest that the MSU/CPPD 
pathway for caspase-1 activation may be mediated by 
microtubule formation, and that blocking this pathway 
may be important for the therapeutic effect of colchicine. 
Where the ATP  and the MSU/CPPD pathways merge is 
an important question that awaits resolution.
Pathogens
Compounds derived from pathogens can also activate 
NALP3. Tschopp and colleagues previously reported 
that the minimal biologically active moiety of bacterial 
peptidoglycan, muramyl dipeptide (MDP), can activate 
caspase-1 in a NALP3-dependent manner in a human 
monocytic cell line (Martinon et al., 2004). However, 
recent studies using macrophages from mice lacking 
NALP3 have not been able to confirm these findings 
(Kanneganti et al., 2006; Mariathasan et al., 2006; Sut-
terwala et al., 2006). Unlike human monocytes, murine 
macrophages did not secrete IL-1β in response to MDP 
alone, and MDP is dispensable for the activation of the 
NALP3-inflammasome in murine macrophages.
Núñez and colleagues have reported that NALP3 and 
ASC are essential for caspase-1 activation by bacte-
rial RNA and the imidazoquinoline compounds, R837 
and R848, but not by LPS, lipoteichoic acid, or bacterial 
lipoprotein, suggesting an important role for the NALP3-
inflammasome in recognition of non-host RNA molecules 
(Kanneganti et al., 2006). However, it should be noted 
that their findings are in marked contrast to those of other 
studies (Mariathasan et al., 2006; Martinon et al., 2006; 
Sutterwala et al., 2006). Firstly, Núñez’s group reported 
that TLR ligands alone (i.e., LPS, lipoteichic acid, bacterial lipoprotein, or imidazoquinoline compounds) could acti-
vate caspase-1 in wild-type murine macrophages without 
the addition of a second stimulus such as ATP, whereas 
the other groups did not observe significant activation of 
caspase-1 by TLR ligands alone. Secondly, in Núñez’s 
study, wild-type macrophages only minimally increased 
IL-1β secretion in response to ATP following stimulation 
with TLR ligands. These differences may be due to subtle 
differences in the protocol used for preparing or stimu-
lating the macrophages. Because bacterial RNA, R837, 
and R848 seem to activate caspase-1 in a manner that is 
distinct from that of ATP and MSU/CPPD, an additional 
pathway leading to activation of the NALP3-inflammas-
ome may exist in macrophages under certain conditions.
Does the NALP3-Inflammasome Sense Danger 
Signals?
ATP, MSU, and CPPD may be endogenous signals 
derived from damaged or dead cells that are sensed 
by the NALP3-inflammasome. The danger signal the-
ory proposes that in addition to foreign objects, the 
immune system senses and responds to damaged cells 
or tissues (Matzinger, 2002). Assuming that the NALP3-
inflammasome is a sensor of danger signals, two recent 
findings on the function of IL-1β can be explained in a 
unified way.
We reported that the NALP3- inflammasome is essen-
tial for the establishment of contact hypersensitivity to the 
hapten trinitrophenylchloride (Sutterwala et al., 2006). In 
these experiments NALP3 and ASC play a role primarily 
at the sensitization phase, although the exact mechanism 
and cell type involved remain unknown. This result is con-
sistent with previous reports demonstrating a critical role 
for IL-1β in the migration of Langerhans’ cells to drain-
ing lymph nodes in response to the hapten fluorescini-
sothiocyanate. This in turn initiates the adaptive immune 
response (Shornick et al., 2001). It has been suggested 
that chemical damage to cells or tissues by the hapten is 
required for the establishment of allergic contact derma-
titis in addition to the antigenicity of the hapten (Smith et 
al., 2002). This suggests that the NALP3-inflammasome 
and IL-1β may play a role in establishing contact hyper-
sensitivity through their ability to recognize and respond 
to a danger signal caused by inflammatory haptens.
Mice lacking MyD88, an adaptor protein recruited to 
the cytoplasmic domain of TLRs and the IL-1 receptor, are 
susceptible to cutaneous infection by S. aureus. Miller et 
al. reported that this susceptibility is more dependent 
on the loss of signaling by the IL-1 receptor than by the 
loss of signaling by TLR2. Moreover, recruitment of neu-
trophils to the lesion, which is caused by IL-1-receptor 
signaling in the skin, plays a critical role for the clearance 
of S. aureus (Miller et al., 2006). Although the source and 
mechanism of IL-1β secretion in these studies was not 
determined, IL-1β secretion by macrophages in response 
to S. aureus was shown to be NALP3 dependent by Mar-
iathasan et al. (2006). By combining these findings, one 
can speculate that the cytotoxic activity of S. aureus rec-Cell 126, August 25, 2006 ©2006 Elsevier Inc. 661
ognized by the NALP3-inflammasome may potentially 
be a more important determinant for the host immune 
system to recruit neutrophils to the infected lesion than 
is the recognition of bacteria by TLRs.
Although caspase-1 clearly plays a role in the patho-
genesis of autoinflammatory disorders such as rheuma-
toid arthritis and CAPS, its role in host defense against 
pathogens is not fully understood. The hypothesis that 
IL-1β and caspase-1 are mediators of danger signals 
may provide new insights into understanding the func-
tion of these factors in innate immune responses.
Multiple Pathways Activate Caspase-1
Recent studies have provided clues as to the mechanism 
of caspase-1 activation by S. typhimurium, Legionella 
pneumophila, Francisella tularensis, and Bacillus anthracis 
(Boyden and Dietrich, 2006; Franchi et al., 2006; Molof-
sky et al., 2006; Ren et al., 2006; Zamboni et al., 2006). 
Importantly, many of these involve NLR/CATERPILLER 
family proteins, which include NALP3 and Ipaf (for a com-
plete review on NLR/CATERPILLER proteins see Ting et 
al., 2006). In addition to bacterial pathogens, viral infec-
tion also induces caspase-1 through an unknown mecha-
nism. Recently, Johnston et al. found that Myxoma virus, 
a poxvirus, carries a protein that inhibits ASC/caspase-1 
activation and subsequent cell death after virus infection. 
Given that poxviruses have evolved specific machinery to 
evade this pathway, ASC may also be important for viral 
elimination (Johnston et al., 2005). Thus, multiple types of 
signals appear to converge at caspase-1 through multiple 
“inflammasomes” (Figure 1).
It remains unclear as to how mature IL-1β, IL-18, and 
IL-33 are released from the cytosol to the extracellular 
space. Two models have been proposed for their secre-
tion: through secretory lysosomes or microvesicle shed-
ding, although no single theory has emerged to unify these 
two models. Because the release of mature IL-1β is linked 
to caspase-1 activation, the inflammasome may func-
tion as a part of the secretion machinery. The role of the 
inflammasome in cytokine release is an important issue 
that remains to be addressed. The exact role of caspase-
1 in programmed cell death is also elusive. Depending on 
the stimulus, the activity of caspase-1 sometimes causes 
cytokine secretion and other times cell death, suggesting 
that there is a cellular machinery that regulates the events 
downstream of caspase-1. The specificity of the effects of 
caspase-1 may be explained by the involvement of differ-
ent types of NLR/CATERPILLER proteins in the formation 
of the activation platform. Elucidating the composition 
and subcellular localization of the inflammasomes may 
provide a clearer insight into the mechanisms leading to 
cytokine secretion and cell death caused by caspase-1.
ACknowLedgMenTS
We thank M. Lara-Tejero, D.S. Zamboni, J.E. Galán, and C.R. Roy for 
fruitful discussions. This work was supported by an Ellison Foundation 
grant (R.A.F.) and the NIH (DK066338-03 to R.A.F.). F.S.S. was sup-
ported by NIAID grant T32 AI-007517. R.A.F. is an HHMI investigator.662 Cell 126, August 25, 2006 ©2006 Elsevier Inc.ReFeRenCeS
Agostini, L., Martinon, F., Burns, K., McDermott, M.F., Hawkins, P.N., 
and Tschopp, J. (2004). Immunity 20, 319–325.
Boyden, E.D., and Dietrich, W.F. (2006). Nat. Genet. 38, 240–244.
Dinarello, C.A. (2002). Clin. Exp. Rheumatol. 20, S1–S13.
Ferrari, D., Pizzirani, C., Adinolfi, E., Lemoli, R.M., Curti, A., Idzko, M., 
Panther, E., and Di Virgilio, F. (2006). J. Immunol. 176, 3877–3883.
Franchi, L., Amer, A., Body-Malapel, M., Kanneganti, T.D., Ozoren, 
N., Jagirdar, R., Inohara, N., Vandenabeele, P., Bertin, J., Coyle, A., 
et al. (2006). Nat. Immunol. 7, 576–582.
Johnston, J.B., Barrett, J.W., Nazarian, S.H., Goodwin, M., Ricuttio, 
D., Wang, G., and McFadden, G. (2005). Immunity 23, 587–598.
Kanneganti, T.D., Ozoren, N., Body-Malapel, M., Amer, A., Park, J.H., 
Franchi, L., Whitfield, J., Barchet, W., Colonna, M., Vandenabeele, P., 
et al. (2006). Nature 440, 233–236.
Mariathasan, S., Newton, K., Monack, D.M., Vucic, D., French, D.M., 
Lee, W.P., Roose-Girma, M., Erickson, S., and Dixit, V.M. (2004). Na-
ture 430, 213–218.
Mariathasan, S., Weiss, D.S., Newton, K., McBride, J., O’Rourke, K., 
Roose-Girma, M., Lee, W.P., Weinrauch, Y., Monack, D.M., and Dixit, 
V.M. (2006). Nature 440, 228–232.
Martinon, F., Agostini, L., Meylan, E., and Tschopp, J. (2004). Curr. 
Biol. 14, 1929–1934.
Martinon, F., Petrilli, V., Mayor, A., Tardivel, A., and Tschopp, J. 
(2006). Nature 440, 237–241.
Matzinger, P. (2002). Science 296, 301–305.
Miao, E.A., Alpuche-Aranda, C.M., Dors, M., Clark, A.E., Bader, 
M.W., Miller, S.I., and Aderem, A. (2006). Nat. Immunol. 7, 569–575.
Miller, L.S., O’Connell, R.M., Gutierrez, M.A., Pietras, E.M., Shahan-
gian, A., Gross, C.E., Thirumala, A., Cheung, A.L., Cheng, G., and 
Modlin, R.L. (2006). Immunity 24, 79–91.
Molofsky, A.B., Byrne, B.G., Whitfield, N.N., Madigan, C.A., Fuse, 
E.T., Tateda, K., and Swanson, M.S. (2006). J. Exp. Med. 203, 1093–
1104.
Ren, T., Zamboni, D.S., Roy, C.R., Dietrich, W.F., and Vance, R.E. 
(2006). PLoS Pathog. 2, e18. 10.1371/journal.ppat.0020018.
Schmitz, J., Owyang, A., Oldham, E., Song, Y., Murphy, E., McCla-
nahan, T.K., Zurawski, G., Moshrefi, M., Qin, J., Li, X., et al. (2005). 
Immunity 23, 479–490.
Shi, Y., Evans, J.E., and Rock, K.L. (2003). Nature 425, 516–521.
Shornick, L.P., Bisarya, A.K., and Chaplin, D.D. (2001). Cell. Immu-
nol. 211, 105–112.
Smith, H.R., Basketter, D.A., and McFadden, J.P. (2002). Clin. Exp. 
Dermatol. 27, 138–146.
Sutterwala, F.S., Ogura, Y., Szczepanik, M., Lara-Tejero, M., Lichten-
berger, G.S., Grant, E.P., Bertin, J., Coyle, A.J., Galán, J.E., Aske-
nase, P.W., and Flavell, R.A. (2006). Immunity 24, 317–327.
Ting, J.P., Kastner, D.L., and Hoffman, H.M. (2006). Nat. Rev. Im-
munol. 6, 183–195.
Yamamoto, M., Yaginuma, K., Tsutsui, H., Sagara, J., Guan, X., Seki, 
E., Yasuda, K., Akira, S., Nakanishi, K., Noda, T., and Taniguchi, S. 
(2004). Genes Cells 9, 1055–1067.
Zamboni, D.S., Kobayashi, K.S., Kohlsdorf, T., Ogura, Y., Long, E.M., 
Vance, R.E., Kuida, K., Mariathasan, S., Dixit, V.M., Flavell, R.A., et 
al. (2006). Nat. Immunol. 7, 318–325.
